Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells, today ...

Brown Convention Center - Exhibit Halls A B About Werewolf Therapeutics Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to ...

Presentation Title: Development of a Surface Engineered Lentiviral Vector for In Vivo Generation of CD22-Directed CAR T Cells Presenting Author: Jeffrey Teoh, Ph.D. Poster Number: 1145 Presentation ...

Brown Convention Center A copy of the presentation materials will be added to the “ Publications ” section of the Company’s website at tscan.com once presentations have concluded. About TScan ...

Poster presentation details: Title: Tumor-activated immune cell engagers designed to drive synthetic immunity against cancer demonstrated protease-dependent activation and robust anti-tumor activity ...

Date: November 9, 2024 Poster Number: 226 Title: An effective donor screening program for manufacturing of allogeneic γδ T cell products Presenter: Inbar Azoulay Alfaguter, Ph.D. (Immatics) ...

MONTREAL, 04 oct. 2024 (GLOBE NEWSWIRE) -- La 36e édition du Shrine Bowl du Canada se tiendra le samedi 5 octobre à 13 h au Stade Concordia, 7200 rue Sherbrooke Ouest à Montréal. Chaque année, ce matc ...

Nouscom has also exclusively out-licensed VAC-85135, an off-the-shelf immunotherapy developed under a multi-project agreement, which is currently under evaluation in a Phase 1 trial for the treatment ...

Pankaj Mohan, Founder and Chief Executive Officer of Sonnet commented, “We are grateful for NJEDA's continued support of the biotechnology industry and to be one of the recipients to benefit from the ...

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based on its T-win ® platform, today announced two ...

Title: NC410 in combination with pembrolizumab improves anti-tumor responses by promoting collagen remodeling and tumor immunity in advanced ICI naive MSS/MSI-L colorectal cancer (CRC) Lead Author: ...

Mr. Crecca commented, “I am excited to join NEXGEL’s Scientific Advisory Board and collaborate with a talented group of individuals to support the development of new therapies leveraging the Company’s ...